Viome Life Sciences
Bothell, Washington, 98011, United States
Location status: Recruiting
Location contact
Momchilo Vuyisich, PhD
CONTACT
Momchilo Vuyisich, PhD
PRINCIPAL_INVESTIGATOR
Mory Mehrtash, MSc
CONTACT
NCT Number: NCT05465616
This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participant recruitment will occur through direct-to-participant enrollment. No additional clinical sites will be used for recruitment.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Bothell, Washington, 98011, United States
Location status: Recruiting
Momchilo Vuyisich, PhD
CONTACT
Momchilo Vuyisich, PhD
PRINCIPAL_INVESTIGATOR
Mory Mehrtash, MSc
CONTACT
This is a randomized, placebo-controlled trial that will test the efficacy of VPNP in reducing HbA1c. Participants with HbA1c levels between 5.7-8.9% (inclusive) will be recruited and randomized into either the placebo or intervention group. The study duration for each participant will be approximately 90 days. At the beginning of the 90 days, the participant will complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to Viome. After the samples are analyzed, the participant will receive dietary recommendations (either personalized or USDA) and supplements (either personalized or placebo). The participant will follow the dietary recommendations and take the supplements for 90 days. At the end of the 90 days, the participant will once again complete online questionnaires, a blood draw, and a set of at-home sample collections for blood, stool, and saliva that will be sent back to Viome for analysis.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nutrition, diet, and possible coaching through Viome application. Precision supplement based on the participants microbiome sample results.
Time frame: 4 months
HbA1c changes in individuals in the interventional arm compared to baseline measurement.
Time frame: 4 months
Change in fasting insulin levels in those in the interventional arm compared to baseline measurement.
Time frame: 4 months
Changes in BMI of individuals in the interventional arm compared to baseline measurement.
Time frame: 4 months
Changes in HDL, LDL, total cholesterol, and triglyceride levels of those in the interventional arm compared to baseline measurements.
Time frame: 4 months
Changes in waist to hip ratio of those in the interventional group compared to baseline measurement.
Time frame: 4 months
Changes to 10 year cardiovascular risk score of those in the interventional arm compared to baseline score.
Time frame: 4 months
Changes in PHQ9 score of those in the interventional arm compared to baseline answers. The minimum PHQ 9 score is 0 and the maximum PHQ 9 score is 27. Higher scores indicate a worse outcome.
Time frame: 4 months
Changes in GAD7 score in those in the interventional arm compared to baseline assessment. The minimum score on GAD 7 is 0-4 indicating none to minimal anxiety and the maximum score is 15-21 indicating sever anxiety. Higher scores indicate a worse outcome.
Time frame: 4 months
Changes in the prevalence of species in stool, blood, and saliva samples compared to baseline analysis.
Time frame: 4 months
Fasting glucose changes in individuals in the interventional arm compared to baseline measurement.
Contact information is provided by the study sponsor or research team.
Momchilo Vuyisich
CONTACT
Mory Mehrtash
CONTACT
Viome
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07111026
Behavior, Behavioral Symptoms
Ellenton, Georgia, United States
View Trial DetailsNCT06657209
Diabetes, Diabetes Mellitus
Palo Alto, California, United States
View Trial DetailsNCT06693934
Body Weight, Cardiovascular Diseases
Hong Kong
View Trial DetailsNCT06710743
Diabetes, Diabetes Mellitus
Sydney, New South Wales, Australia
View Trial Details